Global CAR T Cell Therapy Market Analysis | Industry Report 2026

The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Polaris Market Research.

The report “CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 – 2026” provides deep dive insights on the current market dynamics and gives a detailed analysis on future growth trends of this market.

This market report focuses on CAR-T which is one of the most innovative therapy available in the market which uses the patients’ immune cells to fight cancer.

The WBCs (white blood cells) are extracted – reengineered – injected again into the patient body to fight the malignant cells.

According to the analysis by Polaris Market Research, the potential of the market is ~ $9 billion by 2026, with major focus on Diffuse Large B-Cell Lymphoma (DLBCL) indication in 2020-21.

However, it is expected that the market would also start focusing on Multiple Myeloma (MM) indication and the market for the same is expected to grow at a compounded annual growth rate of more than 80% from 2020 to 2026.

The overall CAR T-cell therapy market size was regarded at USD 4.6 billion out of 2020 and is needed to stretch out at a form yearly improvement rate (CAGR) of 20.2% from 2021 to 2028.

With the underwriting of Yescarta, Kymriah, and Tecartus, a couple of associations have moved their strategies from the improvement of protein and little particle-based prescriptions to consenting medicines.

The expanding endorsements combined with extending producing abilities are expected to heighten the market contest in CAR T-cell treatment organizations in the coming years.

For example, in December 2020, the European Medicine Agency gave an advertising approval to Kite Pharma's Tecartus – the lone CAR-T restorative item for mantle cell lymphoma.

An investigation distributed in December 2020 showed the capability of this treatment to treat high-hazard COVID-19 patients.

Also, in September 2020, the U.S. FDA has cleared the IND application for ALVR109 to treat COVID-19 patients.

Global CAR T cell Therapy Market is projected to reach USD 8716.06 Million by 2025 at a CAGR of 58.52% during the review period from 2019 to 2025.

Chimeric Antigen Receptor (CAR) T Cell Therapy is an immunotherapy used for cancer treatment.

In this therapy, T cells from patient body are isolated and inserted in the CAR gene so that the gene for the specific receptor binds to a certain protein on the patient’s cancer cells.Growing prevalence of cancer across the world, technological advancement for advanced & reliable treatment for cancer, and rise in the number of cell therapy clinical studies are driving the growth of the global CAR T Cell Therapy market.

According to the National Cancer Institute, it is estimated that 1,735,350 new cases of cancer were diagnosed, and 609,640 deaths were reported in the US in 2018.

Moreover, the growing pharmaceutical industry is also expected to boost market growth.Get free Sample @ https://www.marketresearchfuture.com/sample_request/8102Segment AnalysisThe global CAR T cell therapy market, by target antigen, has been segmented into CD19, CD22, and others.

The CD19 target antigen segment accounted for a value of USD 342.56 million in 2018.

Consecutively, the CAR T Cell Therapy market is garnering tremendous traction on a global level.

Increasing funding support from the governments as well as from the private entities for the R to develop and improve the CAR T cell technology predominantly drives the growth of the market.

Global CAR T Cell Therapy Market – SegmentationMRFR has segmented the market into three main dynamics to widen the scope of understanding,By Target Antigen            : CD19, CD22, and others.By Application  : Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, and others.By Regions                          : Europe, Americas, Asia Pacific, Middle East & Africa, and Rest-of-the-World.Global CAR T Cell Therapy Market - Regional AnalysisNorth America is showing chances for retaining its dominance by holding the largest share in the global CAR T cell therapy market throughout the review period.

Moreover, well-defined per capita healthcare expenditure and rising numbers of care facilities offering the therapy alongside the availability of advanced devices contribute to the growth of the regional market.

The US, backed by its vast advancements in CAR T cell therapy, is expected to hold the largest share in the regional as well as in the global market.

Besides, the availability of technologically advanced devices and the proliferating healthcare sector in the region drive the growth of the market.Also, increasing healthcare expenditures and increasing R activities in biotechnology led by the improving economy and the government support in the region contribute to the market growth.

For many years, the support of cancer therapy was chemotherapy, surgery and radiation therapy.

After modification, these immune cells are infused back into the patient as they can easily recognize and kill cancer cells.

These infused cells get multiplied and stay in the body as “living drugs.” According to Renub Research analysis, CAR-T Cell Therapy Market is expected to be USD 7.4 Billion by the end of the year 2028.Growth Factors for CAR-T Cell TherapyFactors such as growing numbers of cancer in adults and children, and increasing policy initiatives to encourage cell therapy research in cancer, and increasing numbers of clinical trials worldwide are some of the main drivers for the global demand for CAR T cell therapy.

The economic scenario in the CAR-T cell therapy industry is very dynamic, and key players compete with each other to gain access to major markets in the United States and Europe.

Companies are seeking to secure treatment facilities to increase access for patients to their treatments.Developments did by Companies in CAR T Cell TherapyIn 2017, a new milestone was set for oncology patients when the FDA approved the first two CD19-targeted known as (Chimeric Antigen Receptor) CAR T cell therapies produced by Novartis and Gilead Sciences known as Kite Pharma in the United States.

Companies are also coming up with new developments in the field.Celgene, a global company, is expected to file for approval in USFDA of bb2121 (idecabtagene vicleucel) in myeloma during the first half of 2020 and lisocabtagene maraleucel in lymphoma in the fourth quarter of 2020.Request a free Brochure copy of the report: https://www.renub.com/request-sample-page.php?gturl=car-t-cell-therapy-market-p.phpRenub Research latest study report “CAR T Cell Therapy Market Global Forecast by Regions (North America, Europe, Asia Pacific, Latin America, Middle East, Africa), Targeted Antigens (CD19, CD20, GD2, CD22, CD30, CD33, HER2, MESO, EGFRvII, Others), Clinical Trials/Study (CD19, CD20, GD2, CD22, CD30, CD33, HER1, HER2, MESO, EGFRvII), Companies (Novartis, Gilead Sciences (Kite Pharma), Celgene Corporation (Juno Therapeutics), Celyad)” provides a detailed and comprehensive insight of the global CAR T cell therapy market.By Antigens – Based on antigens, CAR T Cell Therapy Market is further Segmented into 10 Segments1.

The market is favored by the development of CAR T-cell therapy for several clinical areas such as diffuse large B-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and other cancers or indications.

The increase in the geriatric population and the increasing number of lymphoma and leukemia cases across the globe are expected to translate into a significantly higher demand for the CAR T-cell therapy market.Furthermore, the companies are investing huge amounts in research and development of CAR T-cell therapy either as a monotherapy or as combination therapy.

The clinical trial landscape of various hematologic cancers has been on the rise in recent years, and this will fuel the CAR T-cell therapy market in the futurMarket SegmentationTherapy Application – Diffuse large B-cell lymphoma (DLBCL), Acute lymphoblastic leukemia (ALL), Multiple myeloma (MM), Chronic lymphocytic leukemia (CLL), Follicular lymphoma (FL), Mantle cell lymphoma (MCL), and other cancers or indicationsTarget Antigen – CD19/CD22, BCMA (B-cell maturation antigen), and others target antigensRegional SegmentationNorth America – U.S., CanadaEurope – Germany, France, Italy, U.K., Spain, and Rest-of-EuropeAsia-Pacific – China, Japan, India, South Korea, Australia, and Rest-of-Asia-Pacific (RoAPAC)Latin America – Brazil, Mexico, and Rest-of-the-Latin AmericaRest-of-the-WorldGrowth DriversRising Number of Patients with Hematologic CancersDramatic Rise in Global CAR T-Cell TrialsLandmark Approvals of CAR T-Cell Therapies by the U.S. FDA and the EMAMarket ChallengesHigh Treatment Cost of CAR T-Cell TherapySide Effects of CAR T-Cell TherapyMarket OpportunitiesOpportunities for ImmunotherapyKey Companies ProfiledAmgen, Inc., Autolus Therapeutics plc., Bellicum Pharmaceuticals, Inc., Bluebird Bio Inc., Bristol-Myer Squibb, CARsgen Therapeutics, Ltd., Cartesian Therapeutics, Inc., Cellectis S.A., Celyad Oncology SA, Fortress Biotech, Inc., Janssen Pharmaceuticals, Inc., Kite Pharma, Inc., Legend Biotech Corporation, Novartis AG, and Pfizer, Inc.View Report - https://bisresearch.com/industry-report/car-t-cell-therapy-market.htmlKey Questions Answered in this Report:What is a CAR T-cell?How are CAR T-cells developed?What are the various indications targeted using CAR T-cell therapies?What are the various CAR T-cell therapies available in the market?What are the emerging CAR T-cell therapies for the treatment of hematologic cancers?How does the pipeline for the global CAR T-cell therapy market look like?What is the current market size and future potential of these CAR T-cell therapies?What are the major market drivers, challenges, and opportunities in the global CAR T-cell therapy market?What is the mechanism of action of various CAR T-cell therapies available in the market?What mechanisms of action and molecules are being trialed the most in pipeline products?What are the target antigens in CAR T-cell therapy?How does the clinical trial landscape look for the global CAR T-cell therapy market?What is the patent landscape of this market?

What will be the impact of patent expiry on this market?What is the price structure of CAR T-cell products?What is the total cost of treating a patient with CAR T-cell therapy?What will be the impact of COVID-19 on this market?What are the guidelines implemented by different government bodies to regulate the approval of CAR T-cell therapy?What are the reimbursement scenario and regulatory structure for CAR T-cell therapy?What are the challenges faced by manufacturers in CAR T-cell therapy development?What are the key technological developments on which the current industry leaders are spending a major share of their research and development (R) investments?Which are the leading players currently holding dominating shares in the global CAR T-cell therapy market?What are the key strategies incorporated by the players of the global CAR T-cell therapy market to sustain the competition and retain their supremacy?What is the current revenue contribution of the global CAR T-cell therapy market (by application type), and how is it expected to evolve in the forecast period?What is the current revenue contribution of the global CAR T-cell therapy market (by target antigen), and how is it expected to evolve in the forecast period?Which region is expected to contribute the highest revenue to the global CAR T-cell therapy market during the forecast period?Within the research report, the market is segmented based on application, target antigen, and region.

Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.Get Sample Report - https://bisresearch.com/requestsample?id=1020=download